From GlobeNewswire: 2025-05-30 21:05:00

A recent study by Teva Pharmaceuticals found that over half of LTC residents with TD do not receive standard treatment, with one-quarter left untreated. Many residents are misdiagnosed with EPS, leading to incorrect treatment options. Teva remains committed to advancing research to address unmet needs in TD care. The study analyzed data from residents at risk for TD, revealing gaps in diagnosis and treatment. Only a small percentage of residents received the recommended standard of care, highlighting the need for better evaluation and treatment in LTC settings. Full results were presented at Psych Congress Elevate on May 30, 2025.



Read more at GlobeNewswire: New Data from Teva Shows Substantial Rates of Undertreated